Bioventus Q2 revenue rises 4% to $153.2 million; board starts strategic review
Bioventus reported second-quarter 2026 revenue of $153.2 million, up 4%, and GAAP diluted earnings of $0.47 per share versus $0.11 a year earlier. The company reaffirmed its full-year 2026 guidance and said its board has begun a review of strategic alternatives, including a possible sale, after receiving an unsolicited acquisition proposal. The filing sets no timetable for the review and says there is no assurance it will lead to a transaction.
Key points
- Q2 net sales were $153.2 million, up 3.8%, with Pain Treatments up 11.5% to $81.7 million
- GAAP diluted EPS was $0.47 versus $0.11, helped by removal of a $24.6 million deferred tax valuation allowance; non-GAAP EPS was $0.22 versus $0.21
- 2026 guidance reaffirmed: net sales $600 million to $610 million, adjusted EPS $0.75 to $0.79, cash from operations $84 million to $89 million
- Independent board committee, advised by Evercore and Latham & Watkins, is evaluating a sale or continued standalone plan; no timetable set
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.